BSE · 524506
Coral Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹96 Cr with net profit ₹16 Cr — a 17.1% net margin, versus 19.46% the period before.
Shareholding
As of 2026-09-30
- Promoter71.51%
- Public28.49%
3,913 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.89× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #26 of 51 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,75,920 Cr | 81.03 | 9.53 | 11.42% | 12.27% |
| Gland Pharma Limited | ₹48,848 Cr | 42.63 | 4.72 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹41,906 Cr | 36.93 | 9.24 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹24,989 Cr | 86.71 | 19.46 | 19.14% | 14.89% |
| Caplin Point Laboratories Ltd. | ₹17,881 Cr | 26.88 | 5.31 | 17.88% | 29.09% |
| Shilpa Medicare Ltd. | ₹17,694 Cr | 62.22 | 6.82 | 9.39% | 17.67% |
| Eris Lifesciences Limited | ₹16,626 Cr | 22.21 | 4.01 | 17.07% | 21.36% |
| Marksans Pharma Limited | ₹13,599 Cr | 26.32 | 4.5 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹6,801 Cr | 49.4 | 5.74 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹6,038 Cr | 47.78 | 6.46 | 12.36% | 18.59% |
| Coral Laboratories Ltd.(this company) | ₹175 Cr | 9.25 | 0.84 | 7.83% | 19.87% |
AI analysis
AI-generated · google/gemini-2.5-flashCoral Laboratories Ltd. is listed with a market capitalization of Rs 214 Cr. The company reported a revenue of Rs 124.11 Cr and an EPS of 45.27. As of June 30, 2026, promoter holding stands at 71.5111%.
Positives
- +The debt-to-equity ratio of 0.01 indicates a low level of financial leverage.
- +Promoter holding is 71.5111%, which is above the 50% threshold.
- +Annual revenue increased from Rs 90.2928 Cr in March 2024 to Rs 124.1139 Cr in March 2025.
- +Net profit increased from Rs 15.789 Cr in March 2024 to Rs 24.1556 Cr in March 2025.
- +The dividend yield is 33%, indicating a significant payout to shareholders.
Negatives
- −The company is currently under ESM Stage 1 surveillance.
- −Promoter pledge was 31.83% in March 2018, although it is currently reported as 0.
- −Revenue decreased from Rs 28.13 Cr in March 2025 to Rs 18.82 Cr in June 2025.
- −Net profit decreased from Rs 2.83 Cr in March 2025 to Rs 2.56 Cr in June 2025.
- −The number of shareholders has decreased from 4719 in September 2016 to 3873 in June 2026.
Financial Performance
Coral Laboratories Ltd. reported annual revenue of Rs 124.1139 Cr in March 2025, an increase from Rs 90.2928 Cr in March 2024. Net profit also rose to Rs 24.1556 Cr in March 2025 from Rs 15.789 Cr in March 2024. Quarterly revenue for March 2026 was Rs 26.48 Cr, with a net profit of Rs 5.22 Cr.
Profitability & Returns
The company's profit margin is 19.07%. Return on equity (ROE) is 7.83%, and return on capital employed (ROCE) is 10.8924%. The earnings per share (EPS) for March 2025 was Rs 67.61, up from Rs 44.19 in March 2024.
Balance Sheet
Coral Laboratories Ltd. has a debt-to-equity ratio of 0.01. The book value per share is Rs 585.74.
Ownership & Pledges
Public shareholding is 28.4889%. There are no reported pledged shares by the promoters as of June 30, 2026. Prior promoter pledges were 31.83% in March 2018.
Regulatory & Surveillance
Coral Laboratories Ltd. is currently under ESM Stage 1 surveillance, which indicates enhanced monitoring due to specific market parameters.
Data as of — price: 2026-10-28 · financials: Mar 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.